迈向2030年:SIOP非洲通过全球儿童癌症倡议。

IF 1.2 4区 医学 Q4 HEMATOLOGY Pediatric Hematology and Oncology Pub Date : 2023-04-01 DOI:10.1080/08880018.2022.2117883
Joyce Balagadde-Kambugu, Alan Davidson, Laila Hessissen, Glenn Mbah Afungchwi, Jeannette Parkes, Jaques van Heerden, Jennifer Geel
{"title":"迈向2030年:SIOP非洲通过全球儿童癌症倡议。","authors":"Joyce Balagadde-Kambugu, Alan Davidson, Laila Hessissen, Glenn Mbah Afungchwi, Jeannette Parkes, Jaques van Heerden, Jennifer Geel","doi":"10.1080/08880018.2022.2117883","DOIUrl":null,"url":null,"abstract":"Implementation of the World Health Organization (WHO) Global Initiative for Childhood Cancer (GICC) has galvanized efforts to improve childhood cancer services across Africa, by providing the CureAll framework.1 The benefits to being a GICC implementing country are that attention can be focused on identifying needs by convening stakeholders to define shared objectives, increasing the capacity of a country to manage childhood cancer and developing best practices.1 Ghana, Morocco, Senegal, Zambia and Zimbabwe are currently focus countries with South Africa, Mali, Cameroon and Uganda in the early stages of implementation.2 The acronym CureAll highlights the four essential pillars of the framework: 1) adequately staffed Centers of excellence and care networks, 2) Universal health coverage (UHC) 3) context-appropriate treatment and diagnostic Regimens and roadmaps, and 4) Evaluation and monitoring. These pillars are underpinned by cross-cutting foundational enablers: Advocacy, Leveraged financing, and Linked governance.1 The initiative envisions the unification of diverse stakeholders including patients, families, multidisciplinary pediatric oncology teams and governments, to improve pediatric oncology services. In resource-limited settings, strong leadership is essential in applying available tools in innovative ways to achieve these results. Meeting the 2030 target of 60% survival, double the current estimate, can only be achieved by a unified team approach. SIOP Africa has enthusiastically embraced this framework to improve services for children with cancer and achieve its ambitious goals. Assuming a modest age-standardized ratio of 100 cancers per million children under 15 per year, and a population of 1.2 billion with 40% under the age of 15, there are at least 48 000 new cases in Africa annually.3,4 Many go undiagnosed and report low survival rates, therefore overestimate true survival. Current data only reflect outcomes of those who have accessed services.","PeriodicalId":19746,"journal":{"name":"Pediatric Hematology and Oncology","volume":null,"pages":null},"PeriodicalIF":1.2000,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Toward 2030: SIOP Africa adopts the Global Initiative for Childhood Cancer.\",\"authors\":\"Joyce Balagadde-Kambugu, Alan Davidson, Laila Hessissen, Glenn Mbah Afungchwi, Jeannette Parkes, Jaques van Heerden, Jennifer Geel\",\"doi\":\"10.1080/08880018.2022.2117883\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Implementation of the World Health Organization (WHO) Global Initiative for Childhood Cancer (GICC) has galvanized efforts to improve childhood cancer services across Africa, by providing the CureAll framework.1 The benefits to being a GICC implementing country are that attention can be focused on identifying needs by convening stakeholders to define shared objectives, increasing the capacity of a country to manage childhood cancer and developing best practices.1 Ghana, Morocco, Senegal, Zambia and Zimbabwe are currently focus countries with South Africa, Mali, Cameroon and Uganda in the early stages of implementation.2 The acronym CureAll highlights the four essential pillars of the framework: 1) adequately staffed Centers of excellence and care networks, 2) Universal health coverage (UHC) 3) context-appropriate treatment and diagnostic Regimens and roadmaps, and 4) Evaluation and monitoring. These pillars are underpinned by cross-cutting foundational enablers: Advocacy, Leveraged financing, and Linked governance.1 The initiative envisions the unification of diverse stakeholders including patients, families, multidisciplinary pediatric oncology teams and governments, to improve pediatric oncology services. In resource-limited settings, strong leadership is essential in applying available tools in innovative ways to achieve these results. Meeting the 2030 target of 60% survival, double the current estimate, can only be achieved by a unified team approach. SIOP Africa has enthusiastically embraced this framework to improve services for children with cancer and achieve its ambitious goals. Assuming a modest age-standardized ratio of 100 cancers per million children under 15 per year, and a population of 1.2 billion with 40% under the age of 15, there are at least 48 000 new cases in Africa annually.3,4 Many go undiagnosed and report low survival rates, therefore overestimate true survival. Current data only reflect outcomes of those who have accessed services.\",\"PeriodicalId\":19746,\"journal\":{\"name\":\"Pediatric Hematology and Oncology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2023-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pediatric Hematology and Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/08880018.2022.2117883\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Hematology and Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/08880018.2022.2117883","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Toward 2030: SIOP Africa adopts the Global Initiative for Childhood Cancer.
Implementation of the World Health Organization (WHO) Global Initiative for Childhood Cancer (GICC) has galvanized efforts to improve childhood cancer services across Africa, by providing the CureAll framework.1 The benefits to being a GICC implementing country are that attention can be focused on identifying needs by convening stakeholders to define shared objectives, increasing the capacity of a country to manage childhood cancer and developing best practices.1 Ghana, Morocco, Senegal, Zambia and Zimbabwe are currently focus countries with South Africa, Mali, Cameroon and Uganda in the early stages of implementation.2 The acronym CureAll highlights the four essential pillars of the framework: 1) adequately staffed Centers of excellence and care networks, 2) Universal health coverage (UHC) 3) context-appropriate treatment and diagnostic Regimens and roadmaps, and 4) Evaluation and monitoring. These pillars are underpinned by cross-cutting foundational enablers: Advocacy, Leveraged financing, and Linked governance.1 The initiative envisions the unification of diverse stakeholders including patients, families, multidisciplinary pediatric oncology teams and governments, to improve pediatric oncology services. In resource-limited settings, strong leadership is essential in applying available tools in innovative ways to achieve these results. Meeting the 2030 target of 60% survival, double the current estimate, can only be achieved by a unified team approach. SIOP Africa has enthusiastically embraced this framework to improve services for children with cancer and achieve its ambitious goals. Assuming a modest age-standardized ratio of 100 cancers per million children under 15 per year, and a population of 1.2 billion with 40% under the age of 15, there are at least 48 000 new cases in Africa annually.3,4 Many go undiagnosed and report low survival rates, therefore overestimate true survival. Current data only reflect outcomes of those who have accessed services.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
2.60
自引率
5.90%
发文量
71
审稿时长
6-12 weeks
期刊介绍: PHO: Pediatric Hematology and Oncology covers all aspects of research and patient management within the area of blood disorders and malignant diseases of childhood. Our goal is to make PHO: Pediatric Hematology and Oncology the premier journal for the international community of clinicians and scientists who together aim to define optimal therapeutic strategies for children and young adults with cancer and blood disorders. The journal supports articles that address research in diverse clinical settings, exceptional case studies/series that add novel insights into pathogenesis and/or clinical care, and reviews highlighting discoveries and challenges emerging from consortia and conferences. Clinical studies as well as basic and translational research reports regarding cancer pathogenesis, genetics, molecular diagnostics, pharmacology, stem cells, molecular targeting, cellular and immune therapies and transplantation are of interest. Papers with a focus on supportive care, late effects and on related ethical, legal, psychological, social, cultural, or historical aspects of these fields are also appreciated. Reviews on important developments in the field are welcome. Articles from scientists and clinicians across the international community of Pediatric Hematology and Oncology are considered for publication. The journal is not dependent on or connected with any organization or society. All submissions undergo rigorous peer review prior to publication. Our Editorial Board includes experts in Pediatric Hematology and Oncology representing a wide range of academic and geographic diversity.
期刊最新文献
Hospital acquired venous thromboembolism in children with sickle cell disease. Clonal hematopoiesis of indeterminate potential is rare in pediatric patients undergoing autologous stem cell transplantation. Pseudohyperkalemia in pediatric patients with newly diagnosed hematological malignancies. Utilization of supportive care medications and opportunities for pre-emptive pharmacogenomic testing in pediatric and young adults with leukemia. Hematopoietic Stem Cell Transplantation in Children with Sickle Cell Disease and Thalassemia Major: A National Database Study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1